Introduction
============

Worldwide, the number of diagnosed lung cancer cases amounts to 1.8 million every year. In fact, globally, this is the leading cause of cancer-related deaths ([@b1-ijo-53-01-0113]). Small cell lung cancer (SCLC) accounts for \~15--17% of such lung cancers and is clearly related to cigarette smoking since nearly all SCLC patients were or are active smokers ([@b2-ijo-53-01-0113]). This lung cancer subtype is an aggressive malignancy associated with a poor patient prognosis, with a 5-year survival rate at diagnosis rarely exceeding 15% ([@b3-ijo-53-01-0113],[@b4-ijo-53-01-0113]). Between 75 and 80% of patients suffer from metastatic disease at the time of diagnosis. For this reason, few patients may benefit from curative surgery ([@b4-ijo-53-01-0113]). On the other hand, in the advanced setting, conventional treatment includes combinations of different chemotherapeutic agents such as cisplatin, carboplatin, etoposide, irinotecan, topotecan, doxorubicin, adriamycin or cyclophosphamide ([@b4-ijo-53-01-0113]). Nonetheless, a significant clinical challenge is the extremely frequent development of multi-drug resistance, which makes the chemotherapy ineffective after some time.

During the last few years, evidence has accumulated in regards to the increased antitumoral effect of administering conventional chemotherapy in combination with several antioxidants ([@b5-ijo-53-01-0113],[@b6-ijo-53-01-0113]). Moreover, natural products may be useful anticancer agents. For example, the green tea polyphenol epigallocathechin-3-gallate (EGCG) has been shown in different studies to prevent cancer ([@b7-ijo-53-01-0113]), including lung cancer ([@b8-ijo-53-01-0113]--[@b11-ijo-53-01-0113]). Specifically in regards to SCLC, EGCG has been demonstrated to induce cytotoxicity by the reduction of telomerase activity ([@b12-ijo-53-01-0113]). In addition, DNA fragmentation and apoptosis as well as cell cycle arrest in the S phase were observed. These preclinical *in vitro* data point to the potential use of EGCG in the treatment of SCLC patients.

Ocoxin^®^ oral solution (OOS) is a nutritional supplement whose formulation includes several compounds with anticancer activity, including EGCG ([@b13-ijo-53-01-0113]), vitamin B6, vitamin C, or cinnamic acid ([@b6-ijo-53-01-0113],[@b14-ijo-53-01-0113],[@b15-ijo-53-01-0113]). In addition, OOS contains glycyrrhizinic acid, which exhibits anti-inflammatory and immunomodulatory effects ([@b16-ijo-53-01-0113]). Given such composition, OOS is currently being investigated in clinical trials as part of the treatment of several types of cancer, demonstrating, to date, an improvement in the quality of life of such patients ([@b17-ijo-53-01-0113],[@b18-ijo-53-01-0113]). Moreover, several recent studies have investigated the potential antitumor effect of OOS on different tumor models, including HER2-positive breast cancer ([@b13-ijo-53-01-0113]), acute myeloid leukemia ([@b19-ijo-53-01-0113]) and hepatocellular carcinoma ([@b20-ijo-53-01-0113]). In all these models, OOS exhibited clear antitumor properties both *in vitro* and *in vivo* in xenograft mouse models. At the mechanistic level, OOS seemed to induce a general delay of cell cycle progression. In fact, in breast cancer as well as in AML models, cell cycle blockage seems to be mediated by the increase in the cell cycle inhibitor p27 ([@b13-ijo-53-01-0113],[@b19-ijo-53-01-0113]).

Based on these precedents, the effects of OOS on preclinical models of SCLC were explored. The potential antiproliferative action of this formulation was initially assessed *in vitro* using two different SCLC cell lines alone and in combination with other conventional antitumoral drugs. Its *in vivo* action was analyzed using a xenograft model that showed a reduction in tumor growth in animals that received OOS. Finally, the mechanisms responsible for such decrease were examined both *in vitro* and *in vivo*.

Materials and methods
=====================

Reagents and antibodies
-----------------------

Cell culture media, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), hematoxylin and eosin (H&E) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) and antibiotics were from Life Technologies (Carlsbad, CA, USA) and Immobilon P (PVDF) membranes from Millipore (Billerica, MA, USA). OOS was provided by Catalysis, S.L. (Madrid, Spain). Its formulation included per 50 ml of solution: L-glycine 1,000 mg, glucosamine sulfate 1,000 mg, L-arginine 320 mg, L-cysteine 102 mg, licorice (*Glycyrrhiza glabra* L.) 100 mg, vitamin C (L-ascorbic acid) 60 mg, water, zinc sulfate 40 mg, green tea extract (*Camellia sinensis* L. Kuntze) 12.5 mg, vitamin B5 (D-calcium pantothenate) 6 mg, vitamin B6 (pyridoxine hydrochloride) 2 mg, manganese sulfate 2 mg, cinnamon extract (*Cinnamomum zeylanicum* Blume) 1.5 mg, folic acid (pteroylmonoglutamic acid) 200 *μ*g, vitamin B12 (cyanocobalamin) 1 *μ*g, acidulant (malic acid) and preservative (sodium methylparaben). Other generic chemicals were purchased from Sigma-Aldrich, Roche Biochemicals (Basel, Switzerland) or Merck (Darmstadt, Germany).

The origins of the different antibodies used in the western blot analyses were as follows: the anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (sc-166574, mouse monoclonal, used at 1:10,000) and the anti-PARP (sc-8007, mouse monoclonal, 1:5,000) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); the anti-Rb (\#554136, mouse monoclonal, 1:1,000) and anti-caspase-3 (\#610323, rabbit polyclonal, 1:5,000) from BD Biosciences (Franklin Lakes, NJ, USA) and the anti-p27 (\#3686, rabbit polyclonal, 1:5,000), anti-caspase-8 (\#9746, mouse monoclonal, 1:1,000), anti-caspase-9 (\#9502, rabbit polyclonal, 1:1,000), anti-caspase-7 (\#9492, rabbit polyclonal, 1:1,000), anti-cleaved caspase-3 (\#9664, rabbit polyclonal, 1:1,000) and anti-bid (\#2002, rabbit polyclonal, 1:1,000) from Cell Signaling Technology, Inc. (Danvers, MA, USA). The horseradish peroxidase-conjugated secondary antibodies (goat anti-rabbit, 170-6515, 1:20,000 and goat anti-mouse 170-6516, 1:10,000) were from Bio-Rad Laboratories Inc. (Hercules, CA, USA).

Cell culture, protein extraction and western blotting (WB)
----------------------------------------------------------

SCLC cell lines were grown in RPMI-1640 medium supplemented with 10% FBS and antibiotics. Cells were cultured at 37°C in a humidified atmosphere in the presence of 5% CO~2~-95% air. The two SCLC cell lines used in this study have already been described ([@b21-ijo-53-01-0113]--[@b23-ijo-53-01-0113]) and were generously provided by Dr Clementi (CNR Center of Cytopharmacology, Milan, Italy). Furthermore, GLC-8 cells were initially isolated from a tumor biopsy of an SCLC ([@b22-ijo-53-01-0113]), while DMS 92 cells came from a bone marrow metastasis of an SCLC ([@b21-ijo-53-01-0113]).

To prepare for protein purification, cells were harvested by centrifugation, washed in phosphate-buffered saline (PBS) and lysed in ice-cold lysis buffer ([@b24-ijo-53-01-0113]). Protein quantification, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and WB analysis were performed as previously described ([@b24-ijo-53-01-0113]).

Cell cycle and BrDU incorporation assay
---------------------------------------

For cell cycle analysis by flow cytometry, ethanol-fixed cells were stained with 5 *μ*g/ml propidium iodide (PI) and 250 *μ*g DNase-free RNAse. A total of 50,000 cells were acquired in the PI gate by using a BD Accuri™ C6 flow cytometer and the C6 (version 1.0.264.21) software (BD Biosciences).

To measure bromodeoxyuridine (BrDU) incorporation, the Cell Proliferation ELISA, BrdU (colorimetric) kit (Roche Diagnostics GmbH, Mannheim, Germany) was used following the manufacturer\'s instructions. Data were acquired using a BioTek Synergy 4 reader with Gen5 1.05 software (both from BioTek Instruments, Inc., Winooski, VT, USA).

Assessment of cell death and cell proliferation
-----------------------------------------------

For analysis of apoptotic cell death, GLC-8 cells were treated for 48 h with OOS diluted 1:25 in culture media or left untreated (control), resuspended in binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 nM CaCl~2~, pH 7.4) containing 5 *μ*l Annexin V-FITC (BD Biosciences) and 5 *μ*l 50 *μ*g/ml PI, and stained at room temperature for 15 min. A total of 50,000 cells were acquired using the BD Accuri™ C6 flow cytometer (BD Biosciences) as previously described.

Cell proliferation of SCLC cells was examined using a modified MTT metabolization assay ([@b19-ijo-53-01-0113]). At least three wells were analyzed for each condition, and the results are presented as the mean ± SD of a representative experiment repeated at least twice.

In vivo experiments
-------------------

For the animal studies, 12 7-week-old female athymic mice (CB17-SCID) were purchased from Charles River Laboratories (Wilmington, MA, USA) and maintained in pathogen-free housing at our Institutional Animal Care Facility. Animal experiments were performed according to the institutional guidelines and protocol approved by the Ethics Committee of CSIC-Universidad de Salamanca (Salamanca, Spain). One week later, 6×10^6^ GLC-8 cells resuspended in 50 *μ*l of RPMI-1640 and 50 *μ*l of Matrigel were subcutaneously injected into the right caudal flank of each animal. When tumors became palpable, mice were randomized into two groups (n=6 per group), that were administered vehicle alone (control group) or 100 *μ*l OOS per mouse (20 g). Treatments were administered for 31 days with a daily schedule (Monday to Friday) by oral gavage. Mice were weighed and tumors measured twice a week with a digital caliper (Proinsa, Vitoria, Spain). Tumor volumes were calculated using the following formula: V = (L/2) × (W/2)^2^ × 4/3 × π, where V, volume (cubic mm); L, length (mm); and W, width (mm). At the time of sacrifice, tumor tissue was resected and part of the tumor was immediately frozen at −80°C. Another part was fixed in formalin for further analyses.

Histological and immunohistochemical (IHC) analyses
---------------------------------------------------

Representative tumor areas were fixed in formalin, paraffin-embedded, cut in 2- to 3-*μ*m sections, and either stained with H&E or prepared for IHC, that was performed as previously described ([@b19-ijo-53-01-0113]). Thus, two cell conditioning periods of 8 min at 95°C and 4 min at 100°C on a hot plate using Tris-EDTA (pH 8.0) buffer were performed on previously dewaxed formalin-fixed paraffin-embedded sections. Sections were then incubated with the a 1:50 dilution of an anti-Ki-67 antibody (clon SP6; Master Diagnóstica, Granada, Spain) and the staining was performed with the IHC 3,3′-diaminobenzidine (DAB) system (Ventana Medical Systems, Tucson, AZ, USA). For TUNEL staining, the *In Situ* Cell Death Detection kit (Roche Diagnostics GmbH, Mannheim, Germany) was used, and counterstained with 4′,6-diamino-2-phenylindole. Results were evaluated in a manner blinded to the clinicopathological and molecular data. The number and intensity of immunoreactive cells were evaluated in at least 10 randomly selected fields. These procedures were conducted by independent personnel of the pathology unit of our center. Conflict measurements were solved by consensus.

RNA isolation, cDNA synthesis and microarray hybridization and analysis
-----------------------------------------------------------------------

After thawing, tumors were excised and lysed in TRIzol reagent (Life Technologies), according to the manufacturer\'s instructions. Briefly, tumors were homogenized (Dispomix; L&M Biotech, Holly Springs, NC, USA) and incubated in TRIzol solution for 2 min at room temperature, before the addition of chloroform. Tubes were vigorously shaken and the different phases were separated by centrifugation at 18,000 × g and 4°C for 15 min. The upper, aqueous phase was recovered and the RNA present was precipitated with isopropyl alcohol. Once washed in 70% ethanol, the resultant RNA was column-purified (RNeasy Mini kit; Qiagen, Inc., Valencia, CA, USA) and its integrity was assessed (Agilent 2100 Bioanalyzer; Agilent Technologies, Inc., Santa Clara, CA, USA). Biotinylated complementary RNA was then synthesized (Enzo Life Sciences, Inc., Farmingdale, NY, USA) and hybridized to human Clarion™ S GeneChip oligonucleotide arrays (Affymetrix; Thermo Fisher Scientific, Inc.). Quantitation of fluorescence intensities of probesets was conducted using the GenArray Scanner (Hewlett Packard). Unprocessed files were normalized using the RMA algorithm implemented in the Affymetrix Expression Console (Thermo Fisher Scientific, Inc.). Differentially expressed genes were identified using significant analysis of microarrays, selecting all genes with a value of Q≤0.05.

Statistical analysis
--------------------

Each condition was analyzed in triplicate or quadruplicate and data are presented as the mean ± SD of an experiment that was repeated at least three times. Comparisons of continuous variables between two groups were performed using two-sided Student\'s t-test. Differences were considered to be statistically significant when P-values were \<0.05.

Results
=======

Effect of OOS on the proliferation of SCLC cell lines
-----------------------------------------------------

The *in vitro* action of OOS was evaluated in the SCLC cell lines GLC-8 and DMS 92. With this purpose, cells were grown in the presence of increasing doses of OOS diluted in the culture medium and their proliferation was evaluated using MTT metabolization assays performed at different days of treatment. OOS decreased MTT metabolization in these cells in a time- and dose-dependent manner ([Fig. 1A and C](#f1-ijo-53-01-0113){ref-type="fig"}). The IC~50~ values determined for GLC-8 cells after 4 days and DMS 92 cells after 6 days of treatment were a 1:86 dilution and a 1:60 dilution, respectively ([Fig. 1B and D](#f1-ijo-53-01-0113){ref-type="fig"}).

Effect of OOS in combination with standard of care SCLC treatments
------------------------------------------------------------------

In most of the cases, the success of antitumor therapies is based on the combination of different agents. For this reason, we aimed to ascertain whether the combination of OOS with drugs commonly used in the SCLC clinic could improve their antitumor effect. Thus, GLC-8 cells were treated for 2 days with OOS alone (diluted 1:100 in regular media), or in combination with vincristine (VCR, 5 nM), docetaxel (TXT, 5 nM) or cisplatin (2 or 20 *μ*M). The combination of OOS with this latter compound did not exhibit a superior antiproliferative effect to the one observed for each of the individual treatments (data not shown). In the case of VCR or TXT, the combinations were more effective for inhibiting MTT metabolization than the independent treatment with any of the agents ([Fig. 1E and F](#f1-ijo-53-01-0113){ref-type="fig"}). In fact, when the combination index (CI) of OOS and VCR was calculated using Calcusyn software (Biosoft, Cambridge, UK) an additive effect of both drugs was demonstrated (CI between 0.9 and 0.96, data not shown).

In vivo efficacy of OOS in SCLC murine models
---------------------------------------------

Given the antitumoral action of OOS *in vitro*, we explored whether this effect could also be observed *in vivo*. With this aim, we used a xenograft murine model to determine the effect of OOS treatment once the tumors were already established. CB17-SCID athymic mice were injected with GLC-8 cells and when tumors were palpable and had correctly been engrafted and started to grow, the animals were randomized into two different groups that were orally treated with water (control) or 100 *μ*l OOS per 20 g of animal weight (OOS). Initially, tumors included in the two groups had a similar volume (209.3±17.2 vs. 206.1±16 mm^3^, mean ± SEM, respectively). Tumoral sizes were measured twice a week for a total time period of 31 days. After 14 days of oral treatment with OOS, a significant decrease in the growth of the tumors was observed (p=0.027) ([Fig. 2A](#f2-ijo-53-01-0113){ref-type="fig"}). Nonetheless, such differences increased along the time of treatment. Thus, at the end of the experiment, the mean tumor volume of the control mice was 2,402.6±223.6 mm^3^, as compared with 1,197±144.4 mm^3^ for the group treated with OOS (p=0.003) ([Fig. 2A](#f2-ijo-53-01-0113){ref-type="fig"}). The mean body weight of the control or treated mice did not substantially change throughout the duration of the experiment ([Fig. 2B](#f2-ijo-53-01-0113){ref-type="fig"}), indicative of good tolerability to OOS in our experimental conditions.

Mechanism of action of OOS on SCLC cells
----------------------------------------

The mechanisms leading to the *in vitro* reduction of MTT metabolization were next analyzed. We proposed that such a reduction could be due to an increase in cell death, reduced cell cycle progression or a combination of both. Thus, the capability of OOS to induce apoptotic cell death was assessed. GLC-8 cells were treated for 24 h with OOS diluted at 1:25 in culture medium and apoptotic cell death was determined by double staining with Annexin V and PI. A slight increase in the percentage of cells stained by both Annexin V and PI was observed after OOS treatment (control, 16.7% vs. OOS-treated, 32.0%) ([Fig. 3A](#f3-ijo-53-01-0113){ref-type="fig"}). Analysis of the total viable vs. non-viable population confirmed the induction of cell death by OOS ([Fig. 3B](#f3-ijo-53-01-0113){ref-type="fig"}). Moreover, when the levels of the cleavage of several proteins involved in apoptosis such as PARP or different caspases were determined by western blotting, a clear induction of their proteolytic processing indicative of activation was detected, especially at dilutions of OOS of 1:25 ([Fig. 3C](#f3-ijo-53-01-0113){ref-type="fig"}).

We next investigated whether OOS could induce changes in cell cycle progression. Cells were treated with OOS and cytometrically analyzed after PI staining of the DNA. In those conditions, treatment with OOS resulted in an increase in the G0/G1 population, increasing from 74.8 to 88.5%. Consequently, there was a concomitant decrease in the percentage of cells in the G2/M (from 14.1 to 7.2%) or S phases (from 11.1 to 4.3%) following treatment with OOS ([Fig. 3D](#f3-ijo-53-01-0113){ref-type="fig"}). The capability of OOS to interfere with DNA synthesis was evaluated using an alternative technique that allows the quantification of cells progressing through S phase by the measure of its BrDU incorporation. With this assay, a reduction in the S phase population was demonstrated ([Fig. 3E](#f3-ijo-53-01-0113){ref-type="fig"}), pointing to a slowdown in cell cycle progression as part of the mechanism of action of OOS.

The cell cycle effects of OOS in other cellular models seems to be mediated by an increase in the cell cycle inhibitory protein p27 ([@b13-ijo-53-01-0113],[@b19-ijo-53-01-0113]). To explore whether such a mechanism of action could as well participate in the effect of OOS on SCLC cells, p27 protein levels were determined by western blotting both in control untreated cells or after 24 h of treatment with 1:25 or 1:50 dilutions of OOS. When a dilution factor of 1:25 was used, a clear increase in the p27 level was observed ([Fig. 3F](#f3-ijo-53-01-0113){ref-type="fig"}). Moreover, this increase was correlated with a decrease in the phosphorylation and total levels of the retinoblastoma protein (pRB and RB, respectively) ([Fig. 3F](#f3-ijo-53-01-0113){ref-type="fig"}).

Effect of OOS on cell proliferation and apoptosis in vivo
---------------------------------------------------------

We next investigated the potential mechanisms leading to the decrease in tumor growth observed in OOS-treated animals, when compared to the untreated controls. We first evaluated the general tumor aspects after H&E staining. Independently of whether the animal received treatment of not, the tumoral masses dissected from the animals presented a large central apoptotic/necrotic area that extended to up to 60% of the tumor (data not shown). Tumor cells were in general poorly differentiated, with a high mitotic index. Additionally, control tumors seemed to be better vascularized than OOS-treated ones. In fact, control tumors seemed to be more pseudo-glandular than the treated ones (arrows in [Fig. 4A](#f4-ijo-53-01-0113){ref-type="fig"}). In line with this, tumors from animals which received OOS exhibited a more compact aspect ([Fig. 4A](#f4-ijo-53-01-0113){ref-type="fig"}).

We next evaluated the level of apoptotic cells in the control and OOS-treated animals. While, as mentioned above, when observed under a microscope the central apoptotic/necrotic area observed was similar in both experimental conditions, in OOS-treated tumors more apoptotic regions within non-necrotic tissue could be observed. Analysis of apoptotic cell death after TUNEL staining technique showed that tumors from the OOS-treated animals contained a larger number of apoptotic cells than tumors from untreated animals ([Fig. 4B](#f4-ijo-53-01-0113){ref-type="fig"}). Moreover, quantitative analyses of the TUNEL-stained tumors corroborated that the number of apoptotic cells detected per field was significantly lower in the control condition than that in the treated tumors (p=0.019) ([Fig. 4C](#f4-ijo-53-01-0113){ref-type="fig"}). Together, these data demonstrate that OOS triggers the apoptotic cell death of SCLC cells in the *in vivo* setting.

The expression of human Ki-67, a protein associated with cell proliferation, was also evaluated. Treatment with OOS induced a statistically significant decrease in the percentage of Ki-67-positive cells ([Fig. 4D and E](#f4-ijo-53-01-0113){ref-type="fig"}). The decrease in Ki-67 levels was indicative of a reduced proliferation of OOS-treated tumors.

Transcriptional effect of OOS in vivo
-------------------------------------

To gain further insight into the molecular mechanism leading to the *in vivo* reduction in tumor growth, we investigated the changes in gene expression profiles induced by OOS treatment. Unsupervised clustering of the gene expression data clearly associated samples into two groups, control and OOS-treated, indicating that treatment with OOS was able to change the transcriptome to make treated samples to diverge from the untreated control tumors ([Fig. 5A](#f5-ijo-53-01-0113){ref-type="fig"}). Quantitative comparison of both conditions defined 68 deregulated genes (fold change of at least ±1.5) ([Table I](#tI-ijo-53-01-0113){ref-type="table"}). Volcano plots indicated that among them, 31 genes were upregulated in the control condition whereas 37 were increased after OOS treatment ([Fig. 5B](#f5-ijo-53-01-0113){ref-type="fig"}). Among the deregulated genes, NADH dehydrogenase NDUFA4L2 (2.26-fold higher expression), the ID1 inhibitor of DNA binding (2.2-fold) or ITGB2 (1.7-fold) had a higher expression in the control samples than in those from animals treated with OOS. In contrast, the opposite situation was the olfactory receptor OR51F2 (2.17-fold higher expression in OOS-treated samples) or YBX1 acceptor (2.12-fold), among others ([Table I](#tI-ijo-53-01-0113){ref-type="table"}). Additionally, several intracellular pathways were deregulated, including the DNA damage response pathways, cell cycle regulation, or the PI3K/AKT/mTOR, Wnt or insulin signaling, all of them involved in cell proliferation/apoptosis ([Fig. 5C](#f5-ijo-53-01-0113){ref-type="fig"}). Moreover, when the GSEA software was used to analyze these gene-expression data, the p27 pathway ([Fig. 5D](#f5-ijo-53-01-0113){ref-type="fig"}) and certain pro-apoptotic pathways (data not shown) were found to be upregulated in the OOS-treated tumors. In addition, several angiogenesis-related datasets were downregulated in tumors derived from OOS-treated animals, as shown in [Fig. 5E](#f5-ijo-53-01-0113){ref-type="fig"}.

Discussion
==========

In the present study, we evaluated the antitumoral effect of OOS in SCLC using both *in vitro* and *in vivo* models. OOS induced a clear decrease in MTT metabolization, indicative of an antiproliferative/pro-apoptotic effect in the different SCLC-derived cell lines tested. Such a reduction was both time and dose dependent. Moreover, OOS reduced *in vivo* progression of tumors generated by injection of GLC-8 cells in mice. OOS treatment slowed down tumor growth without signs of major toxicity, since the weights of the control and treated mice were analogous, and no detectable changes in the behavior of the mice were observed.

To explore the mechanisms leading to such tumor growth reduction *in vivo*, several approaches were carried out. First, a general evaluation of tumor characteristics indicated that tumors from control or treated mice exhibited large necrotic/apoptotic areas in the central region of the tumor that is clearly related to the tumor nature, independently of the treatment. Moreover, microscopic inspection of the tumors showed that control tumors seemed to be more vascularized. In fact, treated tumors appeared to be more compact. The presence of blood vessels is extremely important for tumor growth, since those tumor masses larger than a few millimeters in size need these structures for correct nutrient/oxygen supply ([@b25-ijo-53-01-0113]). To evaluate whether such a decrease in blood vessels affected critical oncogenic properties such as survival or proliferation, sections of the tumors were stained with markers of these biological processes. When tumors were stained with the proliferation marker Ki-67, a reduction in proliferating cells after OOS treatment was observed. In addition, a clear increase in cell death was detected under those same conditions after staining for apoptotic cell death by TUNEL. These results point to a combined pro-apoptotic as well as anti-proliferative action of OOS in the SCLC *in vivo* models.

These *in vivo* mechanisms of action were confirmed *in vitro*, where OOS induced both cell death and cell cycle delay. This last action may result from a complex network that regulates cell proliferation, as suggested by the deregulation of several pathways that have been linked to the control of cell proliferation identified in the transcriptomic analyses ([Fig. 6](#f6-ijo-53-01-0113){ref-type="fig"}). Within such a network, one of the actual major players responsible for such anti-proliferative action appears to be the cell cycle inhibitory protein p27. These data corroborate previous studies in which p27 seems to be a key intermediate in OOS anti-proliferative action in other cellular systems such as breast cancer ([@b13-ijo-53-01-0113]), hepatocarcinoma or acute myeloid leukemia ([@b19-ijo-53-01-0113],[@b20-ijo-53-01-0113]).

The success of most antitumor therapies is based on the combination of different agents to increase the antitumor action of the individual agents. With this aim, OOS was used in combination with treatments commonly used in the clinic for SCLC, such as cisplatin, docetaxel or vincristine. When OOS was used together with these last two compounds, a clear potentiation of the antitumor properties was observed, opening the possibility of exploring such effect in patients. This is especially important since most of the patients suffer from metastatic disease at the time of diagnosis and, in those cases, only palliative chemotherapy is offered. For these patients, improvements in the standard of care treatment by the addition of other agents such as OOS could be beneficial as well as a very interesting therapeutic option.

Lung cancer represents the most lethal of all cancers worldwide. The lack of effective treatments, despite recent advances, calls for efforts to improve its management. OOS, which includes several vitamins and antioxidants, could have beneficial effects, always in adequate combination with standard of care therapies. To date, in this study a clear antitumoral effect of OOS on SCLC tumorigenesis has been demonstrated. Moreover, the dual action of the drug that inhibited cell cycle progression and also stimulated cell death may offer therapeutic benefit to the classical drugs used in lung cancer therapy. It would also be valuable to determine whether OOS exerts preventive action on SCLC using, if possible, genetic models for this disease.
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![Efficacy of OOS on SCLC cells *in vitro*. (A) Dose-dependent effect of OOS on the proliferation of GLC-8 cells was assessed *in vitro*. Cells were incubated with OOS at the indicated dilution factors and MTT metabolization was measured as indicated. (B) Calculation of the IC~50~ of OOS. Mean absorbance values of the untreated samples were considered as 100% and the mean values were referred to the control value. (C and D) Similarly, dose-dependent effect of OOS on DMS 92 cells was determined (C) and the IC~50~ value was calculated (D). (E and F) The effect of OOS alone (1:100) or in combination with vincristine \[VCR 5 nM (E)\] or docetaxel \[TXT 5 nM (F)\] were determined by MTT assays. The mean absorbance values of the untreated samples were considered as 100%. Data are represented as mean ± SD of quadruplicates of an experiment that was repeated at least twice. OOS, Ocoxin^®^ oral solution; SCLC, small cell lung cancer; IC~50~, half maximal inhibitory concentration.](IJO-53-01-0113-g00){#f1-ijo-53-01-0113}

![Efficacy of OOS on SCLC models *in vivo*. (A) OOS interferes with tumor growth. Female CB17-SCID athymic mice were injected with 6×10^6^ GLC-8 cells. When tumors became palpable and maintained growth, they were randomized to different groups and were orally treated 5 days per week (Monday to Friday) with 100 *μ*l OOS/animal or vehicle alone (water), and tumor volumes were measured twice a week. Data are represented as mean tumor volume ± SEM of the animals in each group. (B) Effect of OOS on animal weight. Statistical significant differences are shown (^\*^p\<0.05). OOS, Ocoxin^®^ oral solution; SCLC, small cell lung cancer.](IJO-53-01-0113-g01){#f2-ijo-53-01-0113}

![OOS induces cell death as well as cell cycle retardation *in vitro*. (A) GLC-8 cells were treated for 24 h with OOS (1:25), harvested and stained with Annexin V and PI to determine apoptotic cell death. (B) Representation of the viable and non-viable populations of the experiment shown in (A). (C) Quantification of the levels of apoptosis-related proteins after OOS treatment. GLC-8 cells were treated with OOS as in (A) and the levels of the indicated proteins were analyzed by conventional WB. (D) Cell cycle profile of the OOS-treated cells. GLC-8 cells were treated as in (A), harvested, fixed and the DNA content of the living cells was determined by PI staining. (E) OOS treatment caused a decrease in the percentage of cells in the S phase. To measure that population, GLC-8 cells were treated for 24 h with OOS at 1:25 and then incubated in the presence of BrDU for another 3 h. BrDU incorporation was measured using a colorimetric assay as described and normalized to that of the untreated controls. (F) Action of OOS on p27 and retinoblastoma protein (RB) protein levels. GLC-8 cells were treated for 24 h with OOS (1:25 and 1:50 dilution) and cell extracts were prepared to analyze p27 and RB by WB. GAPDH was used as a loading control. OOS, Ocoxin^®^ oral solution; WB, western blotting; PI, propidium iodide.](IJO-53-01-0113-g02){#f3-ijo-53-01-0113}

![OOS induces an increase in cell death and a decrease in proliferation *in vivo*. At the time of sacrifice, part of the tumors from animals shown in [Fig. 2](#f2-ijo-53-01-0113){ref-type="fig"} were fixed and included in paraffin for further analysis. (A) H&E staining of control (left panel) or OOS-treated (right panel) tumors. (B) OOS treatment causes an increase in intratumoral apoptotic cell death. For each experimental condition, two tumors were randomly processed for IHC analysis and apoptotic cells were detected by TUNEL staining. Images of representative fields stained for this marker are shown. (C) The number of apoptotic cells per field was quantified for each condition and its mean number ± SD is shown in the graph. (D) To establish the proliferative status of the tumors, Ki-67 marker was used and images of representative fields stained for Ki-67 are presented. (E) Quantification of the percentage of Ki-67-positive cells from (D). Statistical significant differences are shown (p\<0.05). OOS, Ocoxin^®^ oral solution.](IJO-53-01-0113-g03){#f4-ijo-53-01-0113}

![*In vivo* effect of OOS on gene expression profiles. (A) Hierarchical clustering of the 6 tumors and the 68 genes deregulated after OOS treatment. Each row represents a gene and each column represents a tumor (1, control; 2, OOS-treated). The expression level of each gene in each tumor is relative to its medium abundance across all the tumors and is depicted according to the color scale shown. Red and blue indicate high or low expression levels, respectively. (B) Volcano plot representation of the deregulated genes found in the gene expression profiles. Blue plots represent the 37 genes upregulated in the control condition while red plots represent the 31 ones upregulated in the treated tumors. (C) Pathways *in vivo* deregulated after OOS treatment. Genes found to be deregulated at least 1.5-fold in the Affymetrix Expression Console were analyzed with the same software to evaluate the pathways in which gene expression is altered, and those pathways with a higher number of deregulated genes are shown in the figure. Below each altered pathway, genes upregulated in the control condition (red) or after OOS treatment (green) are shown. Upregulation of the p27 pathway (D) and downregulation of angiogenesis-related genes (E) upon GSEA analysis. OOS, Ocoxin^®^ oral solution.](IJO-53-01-0113-g04){#f5-ijo-53-01-0113}

![Schematic representation of the proposed mechanism of action of OOS in SCLC. OOS exhibits a dual mechanism of action on SCLC both *in vitro* and *in vivo*. OOS induces, on the one hand, an inhibition of cell proliferation due to an increase in the cell cycle inhibitory protein p27 and the deceleration of the cell cycle. Moreover, an increase in caspase-dependent cell death is also stimulated upon OOS treatment. The combination of both actions provokes a decrease in tumor cells both *in vitro* and *in vivo*. OOS, Ocoxin^®^ oral solution; SCLC, small cell lung cancer.](IJO-53-01-0113-g05){#f6-ijo-53-01-0113}

###### 

*In vivo* effect of OOS on gene expression profiles.

  Transcript cluster ID     Control Avg signal   OOS Avg signal   Fold change (C vs. OOS)   ANOVA p-value (C vs. OOS)   FDR p-value (C vs. OOS)   Gene symbol       Description
  ------------------------- -------------------- ---------------- ------------------------- --------------------------- ------------------------- ----------------- ---------------------------------------------------------------------------------------
  TC1200010961.hg.1         6.89                 5.71             2.26                      0.026035                    0.698253                  NDUFA4L2          NADH dehydrogenase (ubiquinone) 1 α subcomplex, 4-like 2
  TC2000007083.hg.1         4.89                 3.75             2.2                       0.00829                     0.698253                  ID1               Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein
  TC2100007394.hg.1         4.84                 4.07             1.7                       0.022428                    0.698253                  ITGB2             Memczak2013 ANTISENSE, CDS, coding, INTERNAL best transcript NM_001127491
  TC1000008663.hg.1         4.99                 4.24             1.69                      0.023254                    0.698253                  SEMA4G            Sema domain (Dom), Ig Dom, transmembrane Dom and short cytoplasmic Dom; semaphorin 4G
  TC1700012281.hg.1         5.62                 4.88             1.68                      0.028637                    0.698253                  EPN3              Epsin 3
  TC0200011898.hg.1         7.56                 6.82             1.67                      0.032135                    0.698253                  SDC1              Syndecan 1
  TC0100013266.hg.1         4.94                 4.22             1.64                      0.02815                     0.698253                  C1orf234          Chromosome 1 open reading frame 234
  TC0X00008694.hg.1         4.67                 3.97             1.63                      0.002167                    0.698253                  HSFX1             Heat shock transcription factor family, X-linked 1
  TC0300013665.hg.1         4.72                 4.03             1.62                      0.010431                    0.698253                  MUC4              Mucin 4, cell surface associated
  TC0X00006567.hg.1         6                    5.3              1.62                      0.03384                     0.698253                  VCX3B; VCX        Variable charge, X-linked 3B; variable charge, X-linked
  TC0400006449.hg.1         6.39                 5.7              1.61                      0.033002                    0.698253                  ZNF141            Transcript Identified by AceView, Entrez Gene ID(s) 100288237; 7700
  TC0Y00007078.hg.1         5.99                 5.31             1.6                       0.038427                    0.698253                  VCY; VCY1B        Variable charge, Y-linked; variable charge, Y-linked 1B
  TC1700010088.hg.1         5.62                 4.94             1.6                       0.0348                      0.698253                  NATD1             N-acetyltransferase domain containing 1
  TC0100006755.hg.1         9.2                  8.54             1.59                      0.013559                    0.698253                  ENO1              Memczak2013 ANTISENSE, coding, INTERNAL, UTR3 best transcript NM_001428
  TC0100018271.hg.1         4.91                 4.24             1.59                      0.045745                    0.698253                  OLFML3            Olfactomedin like 3
  TC0X00006558.hg.1         6.93                 6.26             1.59                      0.017512                    0.698253                  VCX; VCX3A        Variable charge, X-linked; variable charge, X-linked 3A
  TC1100011257.hg.1         6.5                  5.83             1.59                      0.030276                    0.698253                  EFEMP2            EGF containing fibulin-like extracellular matrix protein 2
  TC1700009144.hg.1         6.03                 5.37             1.58                      0.043374                    0.698253                  CHMP6             Charged multivesicular body protein 6
  TC1200012664.hg.1         4.37                 3.72             1.57                      0.047618                    0.698253                  MYRFL             Myelin regulatory factor-like
  TC1900011334.hg.1         4.7                  4.04             1.57                      0.016798                    0.698253                  ZNF677            Zinc finger protein 677
  TC0600009871.hg.1         5.52                 4.88             1.56                      0.029687                    0.698253                  ESR1              Estrogen receptor 1
  TC1900008366.hg.1         6.17                 5.55             1.54                      0.038319                    0.698253                  IGFL1             IGF like family member 1
  TC1900011772.hg.1         6.53                 5.91             1.54                      0.015269                    0.698253                  CRX               Cone-rod homeobox
  TC0200010818.hg.1         6.34                 5.73             1.53                      0.016051                    0.698253                  WNT10A            Wingless-type MMTV integration site family, member 10A
  TC0800012281.hg.1         5.44                 4.84             1.52                      0.004602                    0.698253                  C8orf58           Chromosome 8 open reading frame 58
  TC1900008017.hg.1         6.5                  5.89             1.52                      0.03701                     0.698253                  RYR1              Ryanodine receptor 1 (skeletal)
  TC0100012921.hg.1         7.49                 6.9              1.51                      0.027124                    0.698253                  DHRS3; MIR6730    Dehydrogenase/reductase (SDR family) member 3; microRNA 6730
  TC0X00010933.hg.1         6.1                  5.51             1.51                      0.017036                    0.698253                  ARHGEF6           Rac/Cdc42 guanine nucleotide exchange factor 6
  TC1900007020.hg.1         6.28                 5.68             1.51                      0.03582                     0.698253                  ANGPTL8           Angiopoietin like 8
  TC1900007384.hg.1         6.52                 5.93             1.51                      0.014667                    0.698253                  GDF15             Growth differentiation factor 15
  TC1900011656.hg.1         5.27                 4.67             1.51                      0.001409                    0.698253                  STXBP2            Syntaxin binding protein 2
  TC0300013151.hg.1         5.75                 6.34             −1.51                     0.024943                    0.698253                  NCEH1             Neutral cholesterol ester hydrolase 1
  TC0300013264.hg.1         6.75                 7.34             −1.51                     0.007192                    0.698253                  GNB4              Guanine nucleotide binding protein (G protein), β polypeptide 4
  TC1000007895.hg.1         5.36                 5.96             −1.51                     0.047298                    0.698253                  TSPAN15           Tetraspanin 15
  TC1700011277.hg.1         5.68                 6.27             −1.51                     0.005171                    0.698253                  TRIM37            Transcript Identified by AceView, Entrez Gene ID(s) 4591
  TC1200006454.hg.1         6.08                 6.69             −1.52                     0.017021                    0.698253                  WNK1              Transcript Identified by AceView, Entrez Gene ID(s) 378465; 65125
  TC0600011507.hg.1         6.91                 7.54             −1.55                     0.034697                    0.698253                  PSMB8             Proteasome subunit β8
  TSUnmapped00000243.hg.1   6.34                 6.97             −1.55                     0.041704                    0.698253                  MANSC1            MANSC domain containing 1
  TC0100013902.hg.1         4.58                 5.22             −1.56                     0.039592                    0.698253                  SVBP              Small vasohibin binding protein
  TC0500011513.hg.1         5.24                 5.88             −1.56                     0.003247                    0.698253                  PCSK1             Proprotein convertase subtilisin/kexin type 1
  TC1900011312.hg.1         7.48                 8.12             −1.56                     0.044255                    0.698253                  ZNF611            Zinc finger protein 611
  TC0300013520.hg.1         5.41                 6.08             −1.59                     0.019529                    0.698253                  CLDN1             Claudin 1
  TC0100013223.hg.1         5.83                 6.51             −1.6                      0.027675                    0.698253                  RAP1GAP           RAP1 GTPase activating protein
  TC0X00011080.hg.1         4.29                 4.97             −1.6                      0.010211                    0.698253                  MAGEA9; MAGEA9B   MAGE family member A9; MAGE family member A9B
  TC0800011566.hg.1         5.2                  5.89             −1.61                     0.041099                    0.698253                  RAD21             Transcript Identified by AceView, Entrez Gene ID(s) 5885
  TC1200011870.hg.1         5.78                 6.47             −1.61                     0.030776                    0.698253                  KCTD10            Potassium channel tetramerization domain containing 10
  TC0500007145.hg.1         4.22                 4.92             −1.62                     0.049614                    0.698253                  SKP2              Transcript Identified by AceView, Entrez Gene ID(s) 6502
  TC1200012736.hg.1         3.76                 4.46             −1.63                     0.020998                    0.698253                  ZNF10             Zinc finger protein 10
  TC0400008450.hg.1         5.23                 5.94             −1.64                     0.035161                    0.698253                  ANK2              Ankyrin 2, neuronal
  TC1100006674.hg.1         4.4                  5.13             −1.65                     0.037934                    0.698253                  OR51T1            Olfactory receptor, family 51, subfamily T, member 1
  TC1000009092.hg.1         4.64                 5.38             −1.66                     0.028207                    0.698253                  INPP5F            Inositol polyphosphate-5-phosphatase F
  TC1800009244.hg.1         4.68                 5.41             −1.66                     0.027752                    0.698253                  HMSD              Histocompatibility (minor) serpin domain containing
  TC0900009855.hg.1         4.81                 5.56             −1.69                     0.015155                    0.698253                  BAG1              Bcl-2-associated athanogene
  TC0500009304.hg.1         4.84                 5.62             −1.71                     0.04978                     0.698253                  GABRG2            γ-aminobutyric acid (GABA) A receptor, γ 2
  TC1200010538.hg.1         5.22                 6                −1.72                     0.037044                    0.698253                  AMIGO2            Adhesion molecule with Ig-like domain 2
  TC1400010625.hg.1         4.83                 5.61             −1.72                     0.040343                    0.698253                  ZNF410            Zinc finger protein 410
  TC0400008972.hg.1         4.53                 5.33             −1.74                     0.04379                     0.698253                  DCLK2             Doublecortin-like kinase 2
  TC0200013298.hg.1         5.03                 5.86             −1.78                     0.045777                    0.698253                  ST3GAL5           ST3 β-galactoside α-2.3-sialyltransferase 5
  TC1200009590.hg.1         4.5                  5.34             −1.79                     0.011405                    0.698253                  DCP1B             Decapping mRNA 1B
  TC1400007201.hg.1         6.39                 7.23             −1.79                     0.02332                     0.698253                  CDKN3             Cyclin-dependent kinase inhibitor 3
  TC1500007644.hg.1         4.13                 4.98             −1.79                     0.018087                    0.698253                  C15orf61          Chromosome 15 open reading frame 61
  TC0600008471.hg.1         5.3                  6.16             −1.81                     0.011906                    0.698253                  SDHAF4            Succinate dehydrogenase complex assembly factor 4
  TC0700011796.hg.1         5.17                 6.06             −1.86                     0.037538                    0.698253                  SAMD9             Sterile α motif domain containing 9
  TC0600009019.hg.1         4.77                 5.68             −1.87                     0.00006                     0.429919                  SOBP              Sine oculis binding protein homolog
  TC0400012945.hg.1         5.78                 6.7              −1.9                      0.045226                    0.698253                  HSD17B11          Hydroxysteroid (17-β) dehydrogenase 11
  TC0100008026.hg.1         5.32                 6.4              −2.12                     0.021804                    0.698253                  YBX1              Zhang2013 ALT_ACCEPTOR, ALT_DONOR, coding, INTERNAL, intronic best transcript
  TC1100006671.hg.1         5.76                 6.88             −2.17                     0.021524                    0.698253                  OR51F2            Olfactory receptor, family 51, subfamily F, member 2
  TC0900009779.hg.1         5.16                 6.3              −2.19                     0.030103                    0.698253                  C9orf72           Chromosome 9 open reading frame 72

Comparison of the gene expression profiles of three control tumors to that of three OOS treated ones. Table shows those genes whose expression changed \>1.5 times in that analysis (fold change C vs. OOS). OOS, Ocoxin® oral solution.
